Related Experiment Video

Updated: May 12, 2026

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α
08:26

Development and Validation of an Ultrasensitive Single Molecule Array Digital Enzyme-linked Immunosorbent Assay for Human Interferon-α

Published on: June 14, 2018

Anti-interferon alpha treatment in SLE

Kyriakos A Kirou1, Elena Gkrouzman

  • 1Mary Kirkland Center for Lupus Research, Hospital for Special Surgery, Weill Cornell Medical College, 535 East 70th Street, New York, NY 10021, USA. kirouk@hss.edu

Clinical Immunology (Orlando, Fla.)
|April 10, 2013
PubMed

Several studies in the last decade have highlighted the role of the type I interferon (IFN-I) pathway, and particularly interferon alpha (IFNα) in SLE pathogenesis. As a result, a multitude of potential treatments targeting IFNα have emerged in the last few years, a few of which have already completed phase II clinical trials. Some of the treatment strategies have focused on blocking IFNα or its receptor and others the plasmacytoid dendritic cell (pDC), which is the principal IFNα producing cell. In this review, we will discuss the evidence supporting a pathogenic role of IFNα and pDC in SLE, provide an update on the current status of these therapeutic strategies, and discuss the potential advantages and disadvantages of each therapeutic approach.

Keywords:
AEANAAPECEDB-cell activation factorBAFFBDCA2BILAG indexBritish Isles Lupus Assessment Group indexCCL2CXCL10Clinical trialDCDNAseIFc gamma receptor IIa, GC, glucocorticoidsFcγRIIaGMCSFGRIP1IFN-IIFN-regulated genesIFN-regulatory factorIFN-stimulated response elementIFNARIFNαIFNα KinoidIFNα receptorIFNα-KILILT7IRAKIRFIRGISREIVIgIg-like transcript 7Interferon alphaKLHMHCMajor Histocompatibility ComplexMyD88NETNFκBNKODNPBMCPDPI3KδPlasmacytoid dendritic cellsRBPRDBPCRNA binding proteinsRT-qPCRSAESCSLESLE response indexSRISTATSystemic lupus erythematosusT helper 1TLRTNF alpha-induced protein 3TNFAIP3TNIP1TRAFTYK2Th1Toll-like receptorsUVadverse event(s)antinuclear antibodiesautoimmune polyendocrinopathy candidiasis ectodermal dystrophyblood DC antigen 2chemokine (C–C) motif ligand 2chemokine (C–X–C) motif ligand 10dendritic celldeoxyribonuclease Idouble stranded DNAdsDNAglucocorticoid receptor-interacting protein 1granulocyte/macrophage colony-stimulating factorimmunoglobulininterferon alphainterleukininterleukin receptor associated kinaseintravenouslykeyhole limpet haemocyaninmAbmonoclonal antibodiesmyeloid differentiation factor 88natural killerneutrophil extracellular trapnuclear factor kappa BoligodeoxynucleotidespDCperipheral blood mononuclear cellspharmacodynamicphosphatidylinositol-3 kinase δplasmacytoid dendritic cellrandomized double-blind placebo controlledreal-time quantitative polymerase chain reactionserious adverse event (s)signal transducer and activator of transcriptionsubcutaneouslysystemic lupus erythematosustumor necrosis factor receptor-associated factortumor necrosis factor α-induced protein 3-interacting protein 1type I interferon(s)tyrosine kinase 2ultraviolet

More Related Videos

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes10:00

High-throughput Quantitative Real-time RT-PCR Assay for Determining Expression Profiles of Types I and III Interferon Subtypes

Published on: March 24, 2015

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice04:41

Lumbar Intrathecal Injection of SOD1-ASOs for Precise CNS Targeting and Predictive Efficacy in Human SOD1-G93A ALS Mice

Published on: February 24, 2026

Related Concept Videos

Inhibitors of Viral Protein Synthesis01:30

Inhibitors of Viral Protein Synthesis

Protein synthesis is indispensable for viral replication, as viruses lack the cellular machinery required for this process and must hijack the host's translational apparatus. In response, host cells deploy a critical innate immune defense involving interferons, specialized cytokines that play a central role in inhibiting viral propagation.Upon viral detection, infected cells release interferons that bind to receptors on adjacent uninfected cells, activating the JAK-STAT signaling pathway and...
Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF01:24

Drugs for Treatment of Crohn's Disease in IBD Using Biologic Agents: Anti-TNF

Tumor Necrosis Factor (TNF), a proinflammatory cytokine, contributes significantly to the inflammation seen in Crohn's disease. It exists as soluble TNF and membrane-bound TNF, with actions mediated through TNF receptors (TNFR). TNFR activation leads to the release of proinflammatory cytokines, T-cell activation, collagen production, and leukocyte migration, all contributing to inflammation in Crohn's disease. Anti-TNF monoclonal antibodies, namely infliximab (Remicade), adalimumab (Humira),...
siRNA - Small Interfering RNAs02:30

siRNA - Small Interfering RNAs

Small interfering RNAs, or siRNAs, are short regulatory RNA molecules that can silence genes post-transcriptionally, as well as the transcriptional level in some cases. siRNAs are important for protecting cells against viral infections and silencing transposable genetic elements.
In the cytoplasm, siRNA is processed from a double-stranded RNA, which comes from either endogenous DNA transcription or exogenous sources like a virus. This double-stranded RNA is then cleaved by the ATP-dependent...
Myasthenia Gravis: Overview and Treatment01:20

Myasthenia Gravis: Overview and Treatment

Myasthenia gravis is a neuromuscular transmission disorder characterized by weakness and increased fatigability of skeletal muscles. It is an autoimmune disease affecting approximately one in 2000 people, where antibodies against the α1 subunit of nicotinic acetylcholine receptors are produced.
These antibodies interfere with the function of the nicotinic receptors in three ways: by binding to the receptor and disrupting acetylcholine binding; by causing cross-linking of receptors which leads...
Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...